CAMP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2025Q1

53.00M

-32.49%

-2.070

-250%

54.00M

-23.83%

-1.610

-1420.75%

Estimates Revision

The market is revising No Change the revenue expectations for CalAmp Corp. (CAMP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 63.59%.

Revenue Estimates for FY2024

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2024

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+63.59%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

15.25

High

18.00

Current: 0.000

Low

8.00

Averages

15.25

High

18.00

Canaccord

initiated

$10

2025-12-03

Reason

Canaccord

Price Target

$10

2025-12-03

initiated

Reason

As previously reported, Canaccord initiated coverage of Compass Therapeutics with a Buy rating and $10 price target, telling investors that the firm expects positive data during Q1 0f 2026 for the company's lead asset tovecimig in second-line biliary tract carcinoma. Compass also has two additional assets in the clinic, both of which have shown activity in solid tumors, potentially diversifying revenues long term, the analyst added.

Cantor Fitzgerald

Li Watsek

Overweight

initiated

2025-12-03

Reason

Cantor Fitzgerald

Li Watsek

Price Target

2025-12-03

initiated

Overweight

Reason

Cantor Fitzgerald analyst Li Watsek initiated coverage of Compass Therapeutics with an Overweight rating and no price target. The company is is approaching readouts for its lead bispecific antibody, tovecimig, in late Q1, the analyst tells investors in a research note. Cantor believes the stock "has an asymmetrical setup" into the readout. It believes the Street underestimates the peak sales of tovecimig in second-line biliary tract cancer, which it thinks could reach $712M by 2032.

JPMorgan

Anupam Rama

Overweight -> Neutral

downgrade

2025-09-16

Reason

JPMorgan

Anupam Rama

Price Target

2025-09-16

downgrade

Overweight -> Neutral

Reason

JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics to Neutral from Overweight without a price target. The company's private placement provides a cash runway into 2027, but this is balanced by its the lead program CMP-SYNGAP-01 for Syngap-related disorders being in the very early stage, the analyst tells investors in a research note. JPMorgan now sees a long time horizon to patient level value creation for the shares.

Piper Sandler

Edward Tenthoff

Overweight

downgrade

$18 -> $12

2025-09-15

Reason

Piper Sandler

Edward Tenthoff

Price Target

$18 -> $12

2025-09-15

downgrade

Overweight

Reason

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Camp4 Therapeutics to $12 from $18 and keeps an Overweight rating on the shares. The firm notes Camp4 recently raised $50M bringing pro-form cash to about $86.1M to fund operations into 2027. Participating investors agreed to purchase an additional $50M upon acceptance of the CTA for CPS-SYNGAP-01, which Piper expects in the second half of 2026. The firm is lowering its price target on the shares by increasing value for CMP-SYNGAP-01, reducing value for CMP-CPS-001 and factoring dilution from the recent financing.

Wedbush

NULL -> Outperform

initiated

2025-05-27

Reason

Wedbush

Price Target

2025-05-27

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target.

Wedbush

Yun Zhong

Outperform

initiated

2025-05-27

Reason

Wedbush

Yun Zhong

Price Target

2025-05-27

initiated

Outperform

Reason

Wedbush analyst Yun Zhong initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target. The company's lead candidate CMP-CPS-01 increases the expression of an enzyme for the treatment of urea cycle disorders that affect approximately 20,000 U.S. and European Union patients with no disease modifying treatments available, the analyst tells investors in a research note. The firm says preclinical data show efficient and sustained reduction of ammonia, the root cause of all disease symptoms, and increased expression of additional urea cycle enzymes as well, suggesting approximately 90% of urea cycle disorders patients will be eligible for treatment. Wedbush's calculation suggests approximately 2,000 such patients in the U.S., indicating a $1B opportunity.

Valuation Metrics

The current forward P/E ratio for CAMP4 Therapeutics Corp (CAMP.O) is 0.04, compared to its 5-year average forward P/E of 6.42. For a more detailed relative valuation and DCF analysis to assess CAMP4 Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

6.42

Current PE

0.04

Overvalued PE

152.59

Undervalued PE

-139.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

15.84

Current EV/EBITDA

8.16

Overvalued EV/EBITDA

20.80

Undervalued EV/EBITDA

10.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.60

Current PS

0.00

Overvalued PS

1.09

Undervalued PS

0.12

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CAMP News & Events

Events Timeline

No data

News

1.0

01-06Globenewswire

CAMP4 Therapeutics to Present Corporate Update at J.P. Morgan Healthcare Conference

8.5

2025-12-19Globenewswire

Canadian GoldCamps Corp. Raises $1M and Announces Management Changes

7.5

2025-12-19Benzinga

Analyst: GSK Agreement Confirms the Value of CAMP4's Drug Discovery Platform

People Also Watch

Frequently Asked Questions

What is CAMP4 Therapeutics Corp (CAMP) stock price today?

The current price of CAMP is 6.2 USD — it has increased 0 % in the last trading day.

What is CAMP4 Therapeutics Corp (CAMP)'s business?

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

What is the price predicton of CAMP Stock?

What is CAMP4 Therapeutics Corp (CAMP)'s revenue for the last quarter?

CAMP4 Therapeutics Corp revenue for the last quarter amounts to 858.00K USD, decreased -98.79 % YoY.

What is CAMP4 Therapeutics Corp (CAMP)'s earnings per share (EPS) for the last quarter?

CAMP4 Therapeutics Corp. EPS for the last quarter amounts to -0.62 USD, increased 463.64 % YoY.

What changes have occurred in the market's expectations for CAMP4 Therapeutics Corp (CAMP)'s fundamentals?

How many employees does CAMP4 Therapeutics Corp (CAMP). have?

CAMP4 Therapeutics Corp (CAMP) has 55 emplpoyees as of January 09 2026.

What is CAMP4 Therapeutics Corp (CAMP) market cap?

Today CAMP has the market capitalization of 660.34K USD.